Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

NCT00126893 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00126893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
Lead sponsor
Celgene Corporation
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2005
Completion date
September 30, 2006
Enrollment
36
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia